Histotripsy is a new, FDA-approved, minimally invasive technique that destroys liver tumors using high-frequency ultrasound waves.
For some patients with liver cancer, they could be spared invasive surgery to remove their tumor and instead undergo histotripsy, a novel technique utilizing high-frequency ultrasound waves to destroy tumors, explained Shaun P. McKenzie, MD, FACS, a surgical oncologist with Texas Oncology.
In October 2023 the FDA approved histotripsy for treatment liver tumors based on safety and efficacy of the technique. Histotripsy doesn’t require patients to come off chemotherapy for a long period ahead of or after the treatment, and it also allows for real-time visualization of tumor destruction.
“[For] a lot of treatments that we do, we destroy a tumor but have to wait 3 or 6 months to really know: did we really get it all? Is it destroyed?” McKenzie explained. “Whereas in this treatment, the feedback is immediate, and you can even alter the treatment if you don't feel like you're getting all of the tumor.
Another benefit of histotripsy is its ability to target tumors that are intertwined with critical structures, such as blood vessels and bile ducts, without damaging these essential components, he added.
“While we have a lot more liver than we need, if we start injuring and taking away its ability to have blood flow or its ability to drain the bile that it makes, the liver can go into failure, and that's something that we have to be cautious of,” he said.
In order for the procedure to work, the tumor has to be visible on ultrasound and the patient needs to be able to tolerate general anesthesia, as controlling liver movement during treatment is essential. The actual treatment duration varies, taking between 15 minutes to an hour per tumor.
Recovery from histotripsy is generally easy for most patients, McKenzie said. Patients may experience some soreness and fatigue, but these symptoms typically resolve within a week. In comparison, fatigue may last a month after liver resection.
Inside the Center's MDD Value Model and Its Use of Dynamic Pricing
May 13th 2025Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Listen
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More